Screener
Carlsmed, Inc. CARL Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by Carlsmed, Inc. in its filing.
Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.
The source filing: Carlsmed, Inc.’s 10-Q, filed August 5, 2026. Open the filing →
- Filed
- Aug 5, 2026, 4:10 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001794546-26-000016
FAQ
- What is Carlsmed, Inc.'s cash & equivalents?
- Carlsmed, Inc. (CARL) reported cash & equivalents of $46.24M in Q2 2026.
- How has Carlsmed, Inc.'s cash & equivalents changed year-over-year?
- Carlsmed, Inc.'s cash & equivalents increased by 38.2% year-over-year, from $33.47M to $46.24M.
- What is the long-term trend for Carlsmed, Inc.'s cash & equivalents?
- Over 2 years (2023 to 2025), Carlsmed, Inc.'s cash & equivalents has grown at a 244.7% compound annual growth rate (CAGR), from $7.22M to $85.79M.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.
Ask your AI about Carlsmed, Inc.'s cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude